Trial Profile
Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary) ; Cyclophosphamide; Granulocyte colony-stimulating factors
- Indications Engraftment; Haematological malignancies
- Focus Therapeutic Use
- 12 Apr 2024 Planned End Date changed from 18 May 2025 to 18 Sep 2025.
- 12 Apr 2024 Planned primary completion date changed from 18 May 2024 to 18 Sep 2024.
- 04 Apr 2022 Planned End Date changed from 18 May 2024 to 18 May 2025.